1. S1P/S1PR3 signaling mediated proliferation of pericytes via Ras/pERK pathway and CAY10444 had beneficial effects on spinal cord injury.
- Author
-
Tang HB, Jiang XJ, Wang C, and Liu SC
- Subjects
- Animals, Locomotion drug effects, Lysophospholipids metabolism, MAP Kinase Signaling System drug effects, Pericytes metabolism, Pericytes pathology, Rats, Sprague-Dawley, Receptors, Lysosphingolipid metabolism, Recovery of Function drug effects, Sphingosine analogs & derivatives, Sphingosine metabolism, Sphingosine-1-Phosphate Receptors, Spinal Cord Injuries metabolism, Spinal Cord Injuries pathology, ras Proteins metabolism, Cell Proliferation drug effects, Pericytes drug effects, Receptors, Lysosphingolipid antagonists & inhibitors, Signal Transduction drug effects, Spinal Cord Injuries drug therapy, Thiazolidines therapeutic use
- Abstract
Pericytes have long been regarded merely to maintain structural and functional integrity of blood-brain barrier (BBB). Nevertheless, it has also been identified as a component of scar-forming stromal cells after spinal cord injury (SCI). In process of enlargement of spinal cavity after SCI, the number of pericytes increased and outnumbered astrocytes. However, the mechanism of proliferation of pericytes remains unclear. Sphingosine-1-phosphate (S1P) has been reported to play important roles in the formation of glia scar, but previous studies had paid more attention to the astrocytes. The present study aimed to observe the effects of S1P and S1P receptors (S1PRs) on proliferation of pericytes and investigate the underlying mechanism. By double immunostaining, we found that the number of PDGFRβ-positive pericytes was gradually increased and sealed the cavity, which surrounded by reactive astrocytes. Moreover, the subtype of S1PR3 was found to be induced by SCI and mainly expressed on pericytes. Further, by use of CAY10444, an inhibitor of S1PR3, we showed that S1P/S1PR3 mediated the proliferation of pericytes through Ras/pERK pathway. Moreover, CAY10444 was found to have the effects of enhancing neuronal survival, alleviating glial scar formation, and improving locomotion recovery after SCI. The results suggested that S1P/S1PR3 might be a promising target for clinical therapy for SCI., (Copyright © 2018 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF